Trade

Onesource Specialty Pharma share price

High risk
  • 59%Low risk
  • 59%Moderate risk
  • 59%Balanced risk
  • 59%High risk
  • 59%Extreme risk
  • 1,830.00(0.53%)
    May 15, 2026 15:29:03 PM IST
    • NSE
    • BSE
  • Vol : 297.63 K (NSE + BSE)
    Last 20 day avg : 894.11 K

Onesource Specialty Pharma is trading 0.53% upper at Rs 1,830.00 as compared to its last closing price. Onesource Specialty Pharma has been trading in the price range of 1,860.00 & 1,779.30. Onesource Specialty Pharma has given 0.51% in this year & 0.22% in the last 5 days. There are 4 analysts who have initiated coverage on Onesource Specialty Pharma. There are 3 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 4.60 Crores in its last quarter.Listed peers of Onesource Specialty Pharma include Sun Pharmaceutical Industries (0.90%), Cipla (-0.49%), Divi's Laboratories (-2.41%).The Mutual Fund holding in Onesource Specialty Pharma was at 10.13% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Onesource Specialty Pharma was at 17.50% in 31 Mar 2026. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on May 16, 2026, 04:59 AM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
1,779.30
Highest
1,860.00
52 week range
Lowest
1,075.00
Highest
2,249.65
Onesource Specialty Pharma Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
Bullish
1,879.900.904,51,076.6736.245.770.920.50
Cipla
Moderately Bullish
1,431.55-0.491,16,013.1022.953.870.870.81
Divi's Laboratories
Bullish
6,755.00-2.411,78,679.9978.6111.520.460.01
Torrent Pharmaceuticals
Bullish
4,386.00-0.521,48,148.9267.3217.10.8317.62
Dr Reddy's Laboratories
Bullish
1,336.952.621,11,584.2418.633.140.632.34
Mutual Fund Ownership
View all
Motilal Oswal Manufacturing Fund Regular Growth
NA
  • Amount Invested (Cr.) 33.26
  • % of AUM 4.19
Motilal Oswal Focused Regular Growth
1/5
  • Amount Invested (Cr.) 61.26
  • % of AUM 3.94
Motilal Oswal ELSS Tax Saver Fund Regular Plan Growth
5/5
  • Amount Invested (Cr.) 129.05
  • % of AUM 2.96
JM Focused Fund - Growth Option
2/5
  • Amount Invested (Cr.) 7.90
  • % of AUM 2.83
JM Tax Gain Fund - Growth
4/5
  • Amount Invested (Cr.) 5.42
  • % of AUM 2.73
Onesource Specialty Pharma Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-13Audited Results
2026-01-23Quarterly Results
2025-11-11Quarterly Results
2025-08-04Quarterly Results
2025-05-05Audited Results
About the company Onesource Specialty Pharma
  • IndustryBiotechnology & Drugs
  • ISININE013P01021
  • BSE Code544292
  • NSE CodeONESOURCE
OneSource Specialty Pharma Limited is an India-based vertically integrated biopharma service company with the capabilities to develop and manufacture complex biologics, biosimilars and vaccines. It operates as a specialty pharma pure-play contract development and manufacturing organization (CDMO). The Company specializes in prefilled syringes (with or without a safety device), dial and push variable and fixed dose pen injectors, pull push fixed dose pens and autoinjectors. Its integrated services offer comprehensive biologics solutions. It supports the development of complex biologics, including microbial and mammalian cell line biopharmaceuticals, cell and gene therapy and ribonucleic acid (RNA) products. The Company caters to a variety of capsule shapes and sizes, as well as formulations, traditional softgels to enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories.
  • Management Info
  • Anurag BhaganiaChief Financial Officer
  • Allada TrishaCompany Secretary, Compliance Officer
  • Neeraj SharmaManaging Director, Executive Director
Onesource Specialty Pharma Share Price FAQs

Onesource Specialty Pharma is trading at 1830.00 as on Fri May 15 2026 09:59:03. This is 0.53% upper as compared to its previous closing price of 1820.30.

The market capitalization of Onesource Specialty Pharma is 20979.60 Cr as on Fri May 15 2026 09:59:03.

The average broker rating on Onesource Specialty Pharma is Strong Buy. The breakup of analyst rating is given below -

  • 3 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 0.00 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Onesource Specialty Pharma is 2249.65 whereas the 52 wk low is 1075.00

Onesource Specialty Pharma can be analyzed on the following key metrics -

  • TTM P/E:
  • Sector P/E: -
  • Dividend Yield: 0.00%
  • D/E ratio: 0.26

Onesource Specialty Pharma reported a net profit of -73.80 Cr in 2026.

The Mutual Fund Shareholding was 10.13% at the end of 31 Mar 2026.